These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 18239403

  • 1. Maintenance of medically induced remission of Crohn's disease.
    Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F.
    Digestion; 2007; 76(2):116-29. PubMed ID: 18239403
    [Abstract] [Full Text] [Related]

  • 2. Maintenance of remission in Crohn's disease.
    Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F.
    Digestion; 2005; 71(1):41-8. PubMed ID: 15711049
    [Abstract] [Full Text] [Related]

  • 3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 4. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA.
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [Abstract] [Full Text] [Related]

  • 5. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 6. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS, Zlatanic J, Korelitz BI, Gleim GW.
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [Abstract] [Full Text] [Related]

  • 7. Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.
    Vermeire S, van Assche G, Rutgeerts P.
    Aliment Pharmacol Ther; 2007 Jan 01; 25(1):3-12. PubMed ID: 17229216
    [Abstract] [Full Text] [Related]

  • 8. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ, Feagan BG, Lichtenstein GR.
    Aliment Pharmacol Ther; 2007 Oct 01; 26(7):987-1003. PubMed ID: 17877506
    [Abstract] [Full Text] [Related]

  • 9. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 10. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease.
    Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):343-50. PubMed ID: 16842461
    [Abstract] [Full Text] [Related]

  • 11. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 15; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 12. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 15; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 13. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club.
    Gastroenterology; 2010 Feb 15; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [Abstract] [Full Text] [Related]

  • 14. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 15; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 15. [Drug treatment of Crohn's disease].
    van Deventer SJ, Tytgat GN.
    Ned Tijdschr Geneeskd; 1998 May 23; 142(21):1191-5. PubMed ID: 9627451
    [Abstract] [Full Text] [Related]

  • 16. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 23; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 17. Managing complicated Crohn's disease in children and adolescents.
    Homan M, Baldassano RN, Mamula P.
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec 23; 2(12):572-9. PubMed ID: 16327836
    [Abstract] [Full Text] [Related]

  • 18. Corticosteroid-sparing treatments in patients with Crohn's disease.
    Plevy SE.
    Am J Gastroenterol; 2002 Jul 23; 97(7):1607-17. PubMed ID: 12135008
    [Abstract] [Full Text] [Related]

  • 19. TNF-alpha antagonists: benefits beyond remission.
    Mahadevan U.
    Rev Gastroenterol Disord; 2007 Jul 23; 7 Suppl 1():S13-9. PubMed ID: 17392633
    [Abstract] [Full Text] [Related]

  • 20. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):351-9. PubMed ID: 16842462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.